Maturation of human dendritic cells by cell wall skeleton of Mycobacterium boris bacillus Calmette-Guérin: Involvement of toll-like receptors

Infection and Immunity

Volumn 68, Issue 12, 2000, Pages 6883-6890

  Tsuji, Shoutaro ^a,b   Matsumoto, Misako ^a,b   Takeuchi, Osamu ^c   Akira, Shizuo ^c   Azuma, Ichiro ^d,e   Hayashi, Akira ^a,b   Toyoshima, Kumao ^a   Seya, Tsukasa ^a,b  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b Org Pharmaceutical Safety and Res   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d HOKKAIDO UNIVERSITY   (Japan)

^e HAKODATE NATIONAL COLLEGE OF TECHNOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTATION; ARTICLE; BACTERIAL CELL WALL; CELL MATURATION; DENDRITIC CELL; HUMAN; HUMAN CELL; INFECTION CONTROL; MYCOBACTERIUM BOVIS; PRIORITY JOURNAL; TUBERCULOSIS;

ANTIGEN PRESENTATION; CELL WALL SKELETON; CYTOKINES; DENDRITIC CELLS; DROSOPHILA PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MYCOBACTERIUM BOVIS; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034443265     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.68.12.6883-6890.2000     Document Type: Article

References (45)

1. Alexandroff, A. B., A. M. Jackson, M. A. O'Donnell, and K. James. 1999. BCG immunotherapy of bladder cancer: 20 years on. Lancet 353:1689-1694.
2. Aliprantis, A. O., R. Yang, M. R. Mark, S. Suggett, B. Devaux, J. D. Radolf, G. R. Klimpel, P. Godowski, and A. Zychlinsky. 1999. Cell activation and apoptosis by bacterial lipoproteins through Toll-like receptor-2. Science 285: 736-739.
3. Azuma, I., D. W. Thomas, A. Adam, J. M. Ghuysen, R. Bonaly, J. F. Petit, and G. Lederer. 1970. Occurrence of N-glycolylmuramic acid in bacterial cell walls. Biochim. Biophys. Acta 208:444-451.
4. Azuma, I., E. E. Ribi, T. J. Mejer, and B. Zbar. 1974. Biologically active components from mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3. J. Natl. Cancer Inst. 52:95-101.
5. Azuma, I., H. Okumura, I. Saiki, Y. Tanio, M. Kiso, A. Hasegawa, and Y. Yamamura. 1981. Adjuvant activity of 6-amino-6-deoxy-muramyldipeptides and their acylamino derivatives on the induction of delayed hypersensitivity to azobenzenearsonate-N-acetyl-L-tyrosine in guinea pigs. Infect. Immun. 32:1305-1308.
6. Barnes, P. F., D. Chatterjee, J. S. Abrams, S. Lu, E. Wang, M. Yamamura, P. J. Brennan, and R. L. Modlin. 1992. Cytokine production induced by Mycobacterium tuberculosis lipoarabinomannan. Relationship to chemical structure. J. Immunol. 149:541-547.
7. Bartlett, G. L., J. W. Kreider, and D. M. Purnell. 1976. Relationship between intradermal tumor suppression and tumor immunity. J. Natl. Cancer Inst. 57:1297-1303.
8. Besra, G. S., and D. Chatterjee. 1994. Lipids and carbohydrates of Mycobacterium tuberculosis, p. 285-306. In B. R. Bloom (ed.), Tuberculosis: pathogenesis, protection, and control. American Society for Microbiology, Washington, D.C.
9. Brennan, P. J., and P. Draper. 1994. Ultrastructure of Mycobacterium tuberculosis, p. 271-284. In B. R. Bloom (ed.). Tuberculosis: pathogenesis, protection, and control. American Society for Microbiology, Washington, D.C.
10. Brightbill, H. D., D. H. Libraty, S. R. Krutzik, R. Yang, J. T. Belisle, J. R. Bleharski, M. Maitland, M. V. Norgard, S. E. Plevy, S. T. Smale, P. J. Brennan, B. R. Bloom, P. J. Godowski, and R. L. Modlin. 1999. Host defense mechanisms triggered by microbial lipoproteins through Toll-like receptors. Science 285:732-736.
11. Demangel, C., A. G. D. Bean, E. Martin, C. G. Feng, A. T. Kamath, and W. J. Britton. 1999. Protection against aerosol Mycobacterium tuberculosis infection using Mycobacterium bovis bacillus Calmette Guérin-infected dendritic cells. Eur. J. Immunol. 29:1972-1979.
12. DeVita, V. T., Jr., S. Hellman, and S. A. Rosenberg. 1991. Biological therapy of cancer. J. B. Lippincott, Philadelphia, Pa.
13. Ellouz, F., A. Adam, R. Ciorubaru, and E. Lederer. 1974. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan subunits. Biochem. Biophys. Res. Commun. 59:1317-1325.
14. Freund, J. 1956. The mode of action of immunomologic adjuvants. Adv. Tuberc. Res. 7:130-148.
15. Grand-Perret, T., M. Lepoivre, J. F. Petit, and G. Lemaire. 1986. Macrophage activation by trehalose dimycolate requirement for an expression signal in vitro for antitumoral activity; biochemical markers distinguishing primed and fully activated macrophages. Eur. J. Immunol. 16:332-338.
16. Hawrylko, E. 1975. BCG immunopotentiation of an antitumor response: evidence for a cell-mediated mechanism. J. Natl. Cancer Inst. 55:413-423.
17. Hayashi, A. 1994. Interferon-g as a marker for the effective cancer immunotherapy with BCG-cell wall skeleton. Proc. Jpn. Acad. 70(B):205-209.
18. Hayashi, A., O. Doi, I. Azuma, and K. Toyoshima. 1998. Immuno-friendly use of BCG-cell wall skeleton remarkably improves the survival rate of various cancer patients. Proc. Jpn. Acad. 74(B):50-55.
19. Henderson, R. A., S. C. Watkins, and J. L. Flynn. 1997. Activation of human dendritic cells following infection with Mycohacterium tuberculosis. J. Immunol. 159:635-643.
20. Inaba, K., M. Inaba, M. Naito, and R. M. Steinman. 1993. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. J. Exp. Med. 178:479-488.
21. Kaplan, G., R. R. Gandhi, D. E. Weinstein, W. R. Levis, M. E. Patarroyo, P. J. Brennan, and Z. A. Cohn. 1987. Mycobacterium leprae antigen-induced suppression of T cell proliferation in vitro. J. Immunol. 138:3028-3034.
22. Kaufmann, S. H. E., and J. D. A. van Embden. 1993. Tuberculosis, a neglected disease strikes back. Trends Microbiol. 1:2-5.
23. Kim, K. D., H. G. Lee, J. K. Kim, S. N. Park, I. S. Choe, Y.-K. Choe, S. J. Kim, E. Lee, and J.-S. Lim. 1999. Enhanced antigen-presenting activity and tumor necrosis factor-α-independent activation of dendritic cells following treatment with Mycobacterium bovis bacillus Calmette-Guérin. Immunology 97:626-633.
24. Knutson, K. L., Z. Hmama, P. Herrera-Velit, R. Rochford, and N. E. Reiner. 1998. Lipoarabinomannan of Mycobacterium tuberculosis promotes protein tyrosine dephosphorylation and inhibition of mitogen-activated protein kinase in human mononuclear phagocytes. Role of the Src homology 2 containing tyrosine phosphatase 1. J. Biol. Chem. 273:645-652.
25. Lamensans, A., L. Chedid, E. Lederer, J. P. Rosselet, R. H. Gustafson, H. J. Spencer, B. Ludwig, and F. M. Berger. 1975. Enhancement of immunity against murine syngeneic tumors by a fraction extracted from non-pathogenic mycobacteria. Proc. Natl. Acad. Sci. USA 72:3656-3660.
26. Mathe, G., O. Halle-Pannenko, and C. Bourut. 1973. BCG in cancer immunotherapy: results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immuno-prophylaxis or immunotherapy. Natl. Cancer Inst. Monogr. 39:107-113.
27. Means, T. K., E. Lien, A. Yoshimura, S. Wang, D. T. Golenbock, and M. J. Fenton. 1999. The CD14 ligands lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors. J. Immunol. 163:6748-6755.
28. Means, T. K., S. Wang, E. Lien, A. Yoshimura, D. T. Golenbock, and M. J. Fenton. 1999. Human Toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J. Immunol. 163:3920-3927.
29. Minden, P., and H. L. Mathews. 1980. Suppression and immunotherapy of the guinea pig line 10 hepatocarcinoma mediated by heat-killed disrupted Mycobacterium bovis strain Bacillus Calmette-Guerin. Cancer Res. 40:3214-3217.
30. Oswald, I. P., C. M. Dozois, J. F. Petit, and G. Lemaire. 1997. Interleukin-12 synthesis is a required step in trehalose dimycolate-induced activation of mouse peritoneal macrophages. Infect. Immun. 65:1364-1369.
31. Palucka, K. A., N. Taquet, F. Sanchez-Chapuis, and J. C. Gluckman. 1998. Dendritic cells as the terminal stage of monocytes differentiation. J. Immunol. 160:4587-4595.
32. + peripheral blood monocytes. J. Immunol. 157:3850-3859.
33. Ransom, J. H., B. A. Pelle, H. Hubers, L. M. Keynton, M. G. Hanna, Jr., and N. Pomato. 1993. Identification of colon-tumor-associated antigens by T-cell lines derived from tumor-infiltrating lymphocytes and peripheral-blood lymphocytes from patients immunized with an autologous tumor-cell/bacillus Calmette-Guerin vaccine. Int. J. Cancer 5-4:734-740.
34. Romani, N., S. Gruner, D. Brang, E. Kakumpgen, A. Lenz, B. Trockenbacher, G. Konwalinka, P. O. Fritsch, R. M. Steinman, and G. Schuler. 1994. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180: 83-93.
35. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1109-1118.
36. Schwandner, R., R. Dziarski, H. Wesche, M. Rothe, and C. J. Kirschning. 1999. Peptidoglycan-and lipoteichoic acid-induced cell activation is mediated by Toll-like receptor 2. J. Biol. Chem. 274:17406-17409.
37. Takeuchi, O., K. Hoshino, T. Kawai, H. Sanjo, H. Takeda, T. Ogawa, K. Takeda, and S. Akira. 1999. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 11:443-451.
38. Takizawa, F., S. Tsuji, and S. Nagasawa. 1996. Enhancement of macrophage phagocytosis upon iC3b deposition on apoptotic cells. FEBS Lett. 397:269-272.
39. Thurnher, M., R. Ramoner, G. Gastl, C. Radmayr, G. Beck, M. Herold, H. Klocker, and G. Bartsch. 1997. Bacillus Calmette-Guerin mycobacteria stimulate human blood dendritic cells. Int. J. Cancer 70:128-134.
40. Vermorken, J. B., A. M. Claessen, H. van Tinteren, H. E. Gall, R. Ezinga, S. Meijer, R. J. Scheper, C. J. Meijer, E. Bloemena, J. H. Ransom, M. G. Hanna, Jr., and H. M. Pinedo. 1999. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353:345-350.
41. Yamamura, Y., I. Azuma, T. Taniyama, K. Sugimura, F. Hirao, R. Tokuzen, M. Okabe, W. Nakahara, K. Yasumoto, and M. Ohta. 1976. Immunotherapy of cancer with cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: experimental and clinical results. Ann. N. Y. Acad. Sci. 277:209-227.
42. Yasumoto, K., H. Manabe, E. Yanagawa, N. Nagano, H. Ueda, N. Hirota, M. Ohta, K. Nomoto, I. Azuma, and Y. Yamamura. 1979. Nonspecific adjuvant immunotherapy of lung cancer with cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin. Cancer Res. 39:3262-3267.
43. Yoshimura, A., E. Lien, R. R. Ingalls, E. Tuomanen, R. Dziarski, and D. Golendock. 1999. Recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J. Immunol. 163:1-5.
44. Zbar, B., E. E. Ribi, T. J. Meyer, I. Azuma, and H. J. Rapp. 1974. Immunotherapy of cancer: regression of established intradermal tumors after intralesional injection of mycobacterial cell walls attached to oil droplets. J. Natl. Cancer Inst. 52:1571-1577.
45. + dendritic cells. Proc. Natl. Acad. Sci. USA 93:2588-2592.